scholarly journals Portal vein embolization: rationale, techniques, outcomes and novel strategies

2021 ◽  
pp. HEP42
Author(s):  
Jirapa Chansangrat ◽  
Nattawut Keeratibharat
Keyword(s):  
Interventional Radiology ◽  
Liver Cancer ◽  
Liver Tumors ◽  
Multidisciplinary Management ◽  
Term Survival ◽  
The Third ◽  
The Past ◽  
Management Algorithm ◽  
Interventional Radiology Procedures

The incidence of liver cancer has grown in the past decade, with 905,677 new cases and 830,180 deaths in 2020. According to the highest annual fatality ratio, liver cancer is the third-leading cause of cancer-related deaths worldwide. Surgical resection is the mainstay treatment for long-term survival. However, only 25% of patients are surgical candidates. Recent surgical concepts, techniques and multidisciplinary management were developed, including interventional radiology procedures that improve the management algorithm, expand the indications and limit dropouts from curative treatment. This review summarizes up-to-date information on interventional radiology in the management of liver tumors.

scholarly journals Non-Coding RNAs and Wnt/β-Catenin Signaling Pathway in Gastric Cancer: From EMT to Drug Resistance

Onco ◽  
2021 ◽  
Vol 1 (2) ◽  
pp. 140-157
Author(s):  
Bruno Takao Real Karia ◽  
Camila Albuquerque Pinto ◽  
Carolina Oliveira Gigek ◽  
Fernanda Wisnieski ◽  
Marilia Arruda Cardoso Smith
Keyword(s):  
Gastric Cancer ◽  
Signaling Pathway ◽  
Biological Processes ◽  
Therapeutic Approaches ◽  
Term Survival ◽  
The Third ◽  
The Past ◽  
Sequencing Technologies ◽  
Non Coding Rnas

Gastric cancer is one of the most common cancers and the third cause of cancer-related death worldwide. The treatment of GC patients improved due to advancements in surgery, radiotherapy and chemotherapy. However, the long-term survival rate of patients with gastric cancer remains around 20%. Thus, development of novel therapeutic approaches is of great interest, in order to reduce the need for mutilating surgeries and morbid adjuvant therapies. For many years, it was believed that the RNA was a mere intermediate molecule in the genetic information flow. However, during the past decades, with the advent of new sequencing technologies, it was revealed that non-coding RNAs play important roles in many different biological processes. The Wnt/β-catenin signaling pathway has been reported to regulate crucial events during neoplasic development, such as cell differentiation, proliferation, invasion, migration, apoptosis, and angiogenesis. In this review, we will focus on microRNAs and long non-coding RNAs that have been implicated in gastric cancer tumorigenesis via modulation of the Wnt/β-catenin signaling pathway, which provided some biomarkers to prognosis, diagnosis, and therapy.

Traumatic exungulation in cattle: ten cases (1993–2018)

2021 ◽  
pp. 1-6
Author(s):  
Katharine M. Simpson ◽  
Robert N. Streeter
Keyword(s):  
Clinical Relevance ◽  
Hind Limb ◽  
Clinical Signs ◽  
Clinical Findings ◽  
Teaching Hospitals ◽  
Term Survival ◽  
The Third ◽  
Intended Function ◽  
Hind Limbs

Abstract OBJECTIVE To describe clinical findings, treatments, and outcomes for cattle with complete traumatic exungulation. ANIMALS 10 bovines. PROCEDURES Record databases of 2 teaching hospitals were searched to identify cattle treated for traumatic exungulation between January 1993 and December 2018. Information about signalment, clinical signs and findings, treatment, and outcome was extracted from the records or obtained by telephone communication with the owner. RESULTS Records for 5 bulls, 4 heifers, and 1 cow with a median age of 2 years (range, 1 day to 10 years) and weight of 379.1 kg (range, 30 to 909.1 kg) were reviewed. Duration of clinical signs ranged from ≤ 24 hours to 3.5 days. Five of 7 animals had a lameness score > 3/5. Complete exungulation occurred in 6 medial digits (3 hind limbs and 3 forelimbs) and 5 lateral digits (1 hind limb and 4 forelimbs); 1 calf had complete exungulation of both digits of a forelimb. Treatments included bandaging (n = 9), antimicrobials (9), anti-inflammatories (8), hoof block application to the adjacent digit (7), regional anesthesia (6), cast application (4), curettage of the third phalanx (3), regional antimicrobial perfusion (1), and local application of antimicrobial-impregnated beads (1). All 7 cattle with long-term (≥ 9 months) information available returned to their intended function; 6 had no residual lameness, and 3 required regular corrective trimming of the affected digit. CONCLUSIONS AND CLINICAL RELEVANCE Results suggested the prognosis for long-term survival and return to intended function is fair to good for cattle with complete exungulation.

scholarly journals Evolving impact of long-term survival results on metastatic melanoma treatment

2020 ◽  
Vol 8 (2) ◽  
pp. e000948 ◽  
Author(s):  
Olivier Michielin ◽  
Michael B Atkins ◽  
Henry B Koon ◽  
Reinhard Dummer ◽  
Paolo Antonio Ascierto
Keyword(s):  
Targeted Therapies ◽  
Survival Data ◽  
Long Term Results ◽  
Tumor Type ◽  
Term Survival ◽  
Long Term Survival ◽  
The Past ◽  
Number Of Patients ◽  
Melanoma Treatment

Melanoma treatment has been revolutionized over the past decade. Long-term results with immuno-oncology (I-O) agents and targeted therapies are providing evidence of durable survival for a substantial number of patients. These results have prompted consideration of how best to define long-term benefit and cure. Now more than ever, oncologists should be aware of the long-term outcomes demonstrated with these newer agents and their relevance to treatment decision-making. As the first tumor type for which I-O agents were approved, melanoma has served as a model for other diseases. Accordingly, discussions regarding the value and impact of long-term survival data in patients with melanoma may be relevant in the future to other tumor types. Current findings indicate that, depending on the treatment, over 50% of patients with melanoma may gain durable survival benefit. The best survival outcomes are generally observed in patients with favorable prognostic factors, particularly normal baseline lactate dehydrogenase and/or a low volume of disease. Survival curves from melanoma clinical studies show a plateau at 3 to 4 years, suggesting that patients who are alive at the 3-year landmark (especially in cases in which treatment had been stopped) will likely experience prolonged cancer remission. Quality-of-life and mixture-cure modeling data, as well as metrics such as treatment-free survival, are helping to define the value of this long-term survival. In this review, we describe the current treatment landscape for melanoma and discuss the long-term survival data with immunotherapies and targeted therapies, discussing how to best evaluate the value of long-term survival. We propose that some patients might be considered functionally cured if they have responded to treatment and remained treatment-free for at least 2 years without disease progression. Finally, we consider that, while there have been major advances in the treatment of melanoma in the past decade, there remains a need to improve outcomes for the patients with melanoma who do not experience durable survival.

scholarly journals Long-term survival with tumor regression in androgen-induced liver tumors

Cancer ◽  
1985 ◽  
Vol 56 (11) ◽  
pp. 2622-2626 ◽  
Author(s):  
Geoffrey W. McCaughan ◽  
Michael J. Bilous ◽  
Neil D. Gallagher
Keyword(s):  
Liver Tumors ◽  
Tumor Regression ◽  
Term Survival ◽  
Long Term Survival

The longevity and efficacy of 1080 meat baits used for dingo control in central Australia

2000 ◽  
Vol 27 (5) ◽  
pp. 473 ◽  
Author(s):  
Laurie E. Twigg ◽  
Steve R. Eldridge ◽  
Glenn P. Edwards ◽  
Bernie J. Shakeshaft ◽  
Nicki D. dePreu ◽  
...  
Keyword(s):  
Water Bodies ◽  
Potential Hazard ◽  
Target Species ◽  
Term Survival ◽  
Control Programs ◽  
The Third ◽  
Central Australia ◽  
Considerable Period ◽  
Artificial Water

In central Australia, most 1080 (sodium monofluoroacetate) meat baits placed on soil in predator-proof cages remained toxic to dingoes, foxes and feral cats for at least 8 months regardless of whether they were protected from rain or not. Thus, untaken baits will remain a potential hazard to non-target species, particularly farm dogs, for a considerable period. However, when dingo-control programs were monitored (n = 3 stations), approximately 85% of meat baits were taken within 4 days. Dingo-control programs were undertaken on three stations by placing 1080 meat baits near water points (bores) with known dingo activity. Baiting was effective on two stations but not on the third. Where successful, dingo numbers were reduced by 50–70%. The failure on the third station was not due to the lack of bait-take as approximately 80% of these baits were taken within 4 days; it was probably caused by the presence of ephemeral water-bodies that could not be baited. However, this technique was effective in removing those dingoes that utilised the artificial water points, and hence were likely to be interacting with cattle. Such an outcome has benefits to both conservation and the pastoral industry, as problem dogs are removed without placing the long-term survival of dingoes at risk.

scholarly journals How I treat relapsed acute lymphoblastic leukemia in the pediatric population

Blood ◽  
2020 ◽  
Vol 136 (16) ◽  
pp. 1803-1812 ◽  
Author(s):  
Stephen P. Hunger ◽  
Elizabeth A. Raetz
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Pediatric Population ◽  
Lymphoblastic Leukemia ◽  
Treatment Options ◽  
Survival Rates ◽  
Treatment Decision ◽  
Term Survival ◽  
Hematopoietic Stem ◽  
The Past

Abstract Relapsed acute lymphoblastic leukemia (ALL) has remained challenging to treat in children, with survival rates lagging well behind those observed at initial diagnosis. Although there have been some improvements in outcomes over the past few decades, only ∼50% of children with first relapse of ALL survive long term, and outcomes are much worse with second or later relapses. Recurrences that occur within 3 years of diagnosis and any T-ALL relapses are particularly difficult to salvage. Until recently, treatment options were limited to intensive cytotoxic chemotherapy with or without site-directed radiotherapy and allogeneic hematopoietic stem cell transplantation (HSCT). In the past decade, several promising immunotherapeutics have been developed, changing the treatment landscape for children with relapsed ALL. Current research in this field is focusing on how to best incorporate immunotherapeutics into salvage regimens and investigate long-term survival and side effects, and when these might replace HSCT. As more knowledge is gained about the biology of relapse through comprehensive genomic profiling, incorporation of molecularly targeted therapies is another area of active investigation. These advances in treatment offer real promise for less toxic and more effective therapy for children with relapsed ALL, and we present several cases highlighting contemporary treatment decision-making.

Intensive Asparaginase Therapy in Young Adult Patients with Acute Lymphoblastic Leukemia: Treatment Patterns and Barriers to Asparaginase Use

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 4913-4913
Author(s):  
Leonard S Sender ◽  
Tina Doede ◽  
Megan P. Hall ◽  
Celine Bernard
Keyword(s):  
Overall Survival ◽  
Acute Lymphoblastic Leukemia ◽  
Young Adult ◽  
Lymphoblastic Leukemia ◽  
Adult Patients ◽  
Employment Equity ◽  
Term Survival ◽  
The Past ◽  
Equity Ownership

Abstract Background : Although considerable progress has been made in treating acute lymphoblastic leukemia (ALL) in the pediatric population, with long-term survival exceeding 80%, the prognosis for adolescents, young adult, and adult patients with ALL remains poor, with only 30%-45% of patients achieving long-term survival. Several studies suggest that young adult patients have superior overall survival when treated with intensive "pediatric-inspired" regimens that include the use of asparaginase [Dombret H, et al. Curr Hematol Malig Rep. 2014;9(2):158-164]. Despite these results, many young adult patients with ALL continue to be treated with chemotherapy regimens that include little or no asparaginase. The goal of this study was to assess the views and practices of hematologists and oncologists with respect to asparaginase use in young adult patients with ALL. Methods : This study was conducted between May 14 and June 22, 2015, and consisted of a 10-minute online quantitative survey, with a 10-minute per-patient chart audit component for up to 4 charts provided by participating physicians. The survey targeted physicians treating young adult patients (aged 18-40 years) with ALL. To be included in the final analysis, physicians were required to be board certified with 2-30 years in practice, with ≥75% of their time spent in direct patient care and ≥20% of their time spent in an academic setting (NCCN/NCI or academic/teaching hospital). Inclusion criteria also required that physicians' total ALL patient volume (young adults and adults aged >40 years) was greater than 5 over the past 2 years, that the physician primarily treats adult patients, and has personally managed and treated at least 1 young adult ALL patient in the past 2 years. Results: The study included results reported by a total of 63 practicing physicians for 189 young adult patients with ALL (62% were aged 25-40 years). Sixty percent (114/189) of young adult patients were treated with a protocol that included asparaginase, and only 29% (55/189) on a pediatric-inspired protocol. The most common protocols reported for patients receiving asparaginase included the pediatric-inspired CALGB 10403 (18%, 21/114), as well as regimens with more limited asparaginase use, including augmented hyper-CVAD (29%, 33/114) and CALGB 8811 (12%, 14/114). Overall 40% (75/189) of young adult patients were treated with protocols that did not include asparaginase, most commonly hyper-CVAD (77%, 58/75). Fifty percent (18/36) of responding physicians using hyper-CVAD reported the perception of similar outcomes with nonasparaginase regimens as with asparaginase-intensive regimens. When questioned about the greatest barrier to the use of intensive asparaginase-containing regimens, 88% (7/8) of responding physicians reported safety and tolerability concerns. Conclusion: Only 6 out of 10 patients in the study were treated with an asparaginase-containing regimen; of all patients, less than 1 out of 3 received a pediatric-inspired regimen. Fifty-three percent (60/114) of asparaginase-receiving patients were treated on a regimen that structures asparaginase dosing intermittently between alternating courses. Pediatric-inspired regimens include intensive asparaginase therapy and have consistently shown improvements in overall survival when compared with traditional adult protocols in clinical trials [Dombret H, et al. Curr Hematol Malig Rep. 2014;9(2):158-164]. Support: This study was funded by Jazz Pharmaceuticals. Disclosures Sender: Jazz Pharmaceuticals: Research Funding, Speakers Bureau. Doede:Jazz Pharmaceuticals: Employment, Equity Ownership. Hall:Jazz Pharmaceuticals: Employment, Equity Ownership. Bernard:Jazz Pharmaceuticals: Employment, Equity Ownership.

Adjuvant Chemotherapy in Patients with Osteosarcoma

2011 ◽  
Vol 07 (03) ◽  
pp. 183
Author(s):  
Noah Federman ◽  
William Tap ◽  
◽  
Keyword(s):  
Young Adults ◽  
Adjuvant Chemotherapy ◽  
Malignant Neoplasm ◽  
Chemotherapeutic Agents ◽  
Term Survival ◽  
Future Directions ◽  
The Past ◽  
Metastatic Osteosarcoma ◽  
Improvement In Survival

Osteosarcoma is the most common primary malignant neoplasm of bone in children, adolescents and young adults. Prior to 1970, the outcome for patients with osteosarcoma was dismal, with only 10–20 % of patients achieving long-term survival. The improvement in survival over the past four decades, now approaching 75 %, has largely been due to the addition of adjuvant chemotherapy to surgery. However, for patients that have metastatic osteosarcoma or recurrence of their cancer, the outlook is poor and the prognosis has not improved over the past several decades, despite the advent and use of newer chemotherapeutic agents and combinations. This review will focus on the current chemotherapeutic treatments of localised osteosarcoma, the controversies surrounding adjuvant therapy and future directions and additions to our armamentarium.

Sign in / Sign up

Export Citation Format

Share Document